Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,895,262 papers from all fields of science
Search
Sign In
Create Free Account
PM02734
Known as:
Depsipeptide PM02734
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Irvalec
elisidepsin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
M. Ratain
,
David Geary
,
+5 authors
B. Miguel-Lillo
Investigational new drugs
2015
Corpus ID: 905663
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase…
Expand
2013
2013
Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound
M. Serova
,
A. de Gramont
,
+6 authors
E. Raymond
Marine Drugs
2013
Corpus ID: 9519256
Elisidepsin (PM02734, Irvalec®) is a synthetic marine-derived cyclic peptide of the Kahalalide F family currently in phase II…
Expand
2012
2012
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
R. Salazar
,
R. Jones
,
+9 authors
T. Evans
Cancer Chemotherapy and Pharmacology
2012
Corpus ID: 24422950
PurposeTo determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of…
Expand
Highly Cited
2011
Highly Cited
2011
PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase
Y. Ling
,
M. Aracil
,
+5 authors
R. Perez-soler
Clinical Cancer Research
2011
Corpus ID: 15247962
Purpose: PM02734 (elisidepsin) is a synthetic marine-derived cyclic peptide of the kahalalide family currently in phase II…
Expand
2009
2009
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Y. Ling
,
M. Aracil
,
J. Jimeno
,
R. Perez-soler
,
Y. Zou
European Journal of Cancer
2009
Corpus ID: 207211352
Review
2009
Review
2009
Cancer treatments: can we find treasures at the bottom of the sea?
M. Provencio
,
Antonio C Sánchez
,
J. Gasent
,
Patricia Gómez
,
R. Rosell
Clinical Lung Cancer
2009
Corpus ID: 7035068
Because of the poor results observed after platinum-based first-line chemotherapy, research on new strategies for second-line…
Expand
2008
2008
Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734.
A. Herrero
,
A. Astudillo
,
M. Balboa
,
C. Cuevas
,
J. Balsinde
,
S. Moreno
Cancer Research
2008
Corpus ID: 14105933
PM02734 is a novel synthetic antitumor drug that is currently in phase I clinical trials. To gain some insight into its mode of…
Expand
2008
2008
Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations
J. Bruce
,
David Geary
,
+6 authors
M. Ratain
2008
Corpus ID: 74455729
2513 Background: PM02734 is a chemically synthesized depsipeptide with a broad spectrum of activity against solid tumors in vitro…
Expand
2006
2006
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma.
Jianming Yin
,
P. Avilés
,
+5 authors
G. Faircloth
Rapid Communications in Mass Spectrometry
2006
Corpus ID: 13051498
A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay was developed and validated to quantify a…
Expand
2006
2006
Activity of pm02734 against human breast and prostate tumors
M. Elices
,
D. Lepage
,
+5 authors
G. Faircloth
2006
Corpus ID: 53855847
4712 The novel investigational agent PM02734 is a member of the Kahalalide F family of compounds that display marked anttumor…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE